Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333802 | 0.89 | MAOA (0.49) | KDM4EALDH1A1MAPTMAPK1BCHE | |
| SCHEMBL10696872 | 0.84 | ALDH1A1 (0.63) | HRH3KDM4EALDH1A1MAPTHRH4 | |
| SCHEMBL10701011 | 0.82 | ALDH1A1 (0.51) | HRH3KDM4EALDH1A1HRH4HTT | |
| SCHEMBL10698243 | 0.82 | ALDH1A1 (0.53) | HRH3KDM4EALDH1A1HRH4MAPK1 | |
| SCHEMBL1808667 | 0.81 | SIGMAR1 (0.57) | HRH3KDM4EALDH1A1BCHEACHE | |
| SCHEMBL5319459 | 0.81 | HRH3 (0.74) | HRH3KDM4EALDH1A1MAPTMCHR1 | |
| Hydrochloric Acid SCHEMBL23850153 | 0.79 | HRH3 (0.64) | HRH3KDM4EALDH1A1MAPTMCHR1 | |
| SCHEMBL6731656 | 0.79 | HRH3 (0.78) | HRH3KDM4EALDH1A1MCHR1HRH4 | |
| SCHEMBL1505875 | 0.79 | HRH3 (0.78) | HRH3KDM4EALDH1A1MCHR1HRH4 | |
| SCHEMBL1429999 | 0.79 | HRH3 (0.49) | HRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| CN-100450483-C | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2009-01-14 | — | — | CN | disclosed |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | disclosed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-0280873-A1 | Piperidines, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144696-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | HRH3 665/4885KDM4E 1464/4885ALDH1A1 2209/4885 |
| US-20100144697-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | HRH3 665/4885KDM4E 1464/4885ALDH1A1 2209/4885 |
| US-20070142442-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1C, CACNA1S, CACNA1B | HRH3 665/4885KDM4E 1464/4885ALDH1A1 2209/4885 |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | HRH3 1355/4885KDM4E 1026/4885ALDH1A1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.